A Phase I Study of LFA102 in Japanese Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Castration-resistant Prostate Cancer, Advanced Breast Cancer
Interventions: DRUG: LFA102
Sponsor: Novartis Pharmaceuticals